70 related articles for article (PubMed ID: 21144477)
1. [The Alzheimer's disease: how to estimate the impact of the pathology and the treatment?].
Delrieu J; Vellas B
Therapie; 2010; 65(5):423-8. PubMed ID: 21144477
[TBL] [Abstract][Full Text] [Related]
2. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of Alzheimer's disease and future approaches].
Forette F; Hauw JJ
Therapie; 2010; 65(5):429-37. PubMed ID: 21144478
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers in Alzheimer's disease: not yet surrogate endpoints.
Coley N; Andrieu S; Delrieu J; Voisin T; Vellas B
Ann N Y Acad Sci; 2009 Oct; 1180():119-24. PubMed ID: 19906266
[TBL] [Abstract][Full Text] [Related]
5. Navigating patients and caregivers through the course of Alzheimer's disease.
Aupperle PM
J Clin Psychiatry; 2006; 67 Suppl 3():8-14; quiz 23. PubMed ID: 16649846
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers in preclinical Alzheimer's disease.
Chong MS; Lim WS; Sahadevan S
Curr Opin Investig Drugs; 2006 Jul; 7(7):600-7. PubMed ID: 16869111
[TBL] [Abstract][Full Text] [Related]
7. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.
Andreasen N; Blennow K
Clin Neurol Neurosurg; 2005 Apr; 107(3):165-73. PubMed ID: 15823670
[TBL] [Abstract][Full Text] [Related]
8. Imaging and biomarkers for Alzheimer's disease.
Allan CL; Sexton CE; Welchew D; Ebmeier KP
Maturitas; 2010 Feb; 65(2):138-42. PubMed ID: 20060241
[TBL] [Abstract][Full Text] [Related]
9. Imaging is superior to cognitive testing for early diagnosis of Alzheimer's disease.
Zamrini E; De Santi S; Tolar M
Neurobiol Aging; 2004; 25(5):685-91. PubMed ID: 15172748
[TBL] [Abstract][Full Text] [Related]
10. Mild cognitive impairment and preclinical Alzheimer's disease.
Morris JC
Geriatrics; 2005 Jun; Suppl():9-14. PubMed ID: 16025770
[TBL] [Abstract][Full Text] [Related]
11. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment.
DeKosky ST; Ikonomovic MD; Wang X; Farlow M; Wisniewski S; Lopez OL; Becker JT; Saxton J; Klunk WE; Sweet R; Kaufer DI; Kamboh MI
Ann Neurol; 2003 Jan; 53(1):81-90. PubMed ID: 12509851
[TBL] [Abstract][Full Text] [Related]
12. Advances in the early detection of Alzheimer's disease.
Nestor PJ; Scheltens P; Hodges JR
Nat Med; 2004 Jul; 10 Suppl():S34-41. PubMed ID: 15298007
[TBL] [Abstract][Full Text] [Related]
13. Defining and labeling disease-modifying treatments for Alzheimer's disease.
Cummings JL
Alzheimers Dement; 2009 Sep; 5(5):406-18. PubMed ID: 19751920
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
Hansson O; Zetterberg H; Vanmechelen E; Vanderstichele H; Andreasson U; Londos E; Wallin A; Minthon L; Blennow K
Neurobiol Aging; 2010 Mar; 31(3):357-67. PubMed ID: 18486992
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A
Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118
[TBL] [Abstract][Full Text] [Related]
16. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
17. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms.
Amieva H; Le Goff M; Millet X; Orgogozo JM; Pérès K; Barberger-Gateau P; Jacqmin-Gadda H; Dartigues JF
Ann Neurol; 2008 Nov; 64(5):492-8. PubMed ID: 19067364
[TBL] [Abstract][Full Text] [Related]
18. [Early diagnosis and the course of Alzheimer's disease].
Sánchez JL; Sayago AM
Rev Neurol; 2000 Jan 16-31; 30(2):121-7. PubMed ID: 10730317
[TBL] [Abstract][Full Text] [Related]
19. Workgroup on NAPA's scientific agenda for a national initiative on Alzheimer's disease.
Alzheimer's Association Expert Advisory Workgroup on NAPA
Alzheimers Dement; 2012 Jul; 8(4):357-71. PubMed ID: 22748940
[TBL] [Abstract][Full Text] [Related]
20. Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine.
Flood DG; Marek GJ; Williams M
Biochem Pharmacol; 2011 Jun; 81(12):1422-34. PubMed ID: 21295552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
